Olaratumab - Biologic Drug Details

Summary for olaratumab

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for olaratumab

Recent Clinical Trials for olaratumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Telix Pharmaceuticals (Innovations) Pty Ltd	PHASE1
University of Miami	Phase 1
Janssen Scientific Affairs, LLC	Phase 1

See all olaratumab clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for olaratumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for olaratumab Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Eli Lilly And Company	LARTRUVO	olaratumab	Injection	761038	8,128,929	2026-06-19	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	LARTRUVO	olaratumab	Injection	761038	8,574,578	2031-10-19	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for olaratumab Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Eli Lilly And Company	LARTRUVO	olaratumab	Injection	761038	10,047,163	2034-02-07	Patent claims search
Eli Lilly And Company	LARTRUVO	olaratumab	Injection	761038	10,111,968	2036-08-10	Patent claims search
Eli Lilly And Company	LARTRUVO	olaratumab	Injection	761038	10,590,182	2036-02-23	Patent claims search

International Patents for olaratumab

Country	Patent Number	Estimated Expiration
Brazil	PI0611984
Brazil	PI0622073
Brazil	PI0622074

Supplementary Protection Certificates for olaratumab

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C 2017 013	Romania		PRODUCT NAME: OLARATUMAB; NATIONAL AUTHORISATION NUMBER: EU/1/16/1143; DATE OF NATIONAL AUTHORISATION: 20161109; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/16/1143; DATE OF FIRST AUTHORISATION IN EEA: 20161109
311 50005-2017	Slovakia		PRODUCT NAME: OLARATUMAB; REGISTRATION NO/DATE: EU/1/16/1143 20161111
620	Finland

Last updated: February 15, 2026

What Are the Market Dynamics for Olaratumab?

Olaratumab, a monoclonal antibody targeting platelet-derived growth factor receptor alpha (PDGFRα), was developed as a treatment for soft tissue sarcoma (STS). Its market presence is shaped by clinical efficacy, regulatory decisions, competition, and the broader treatment landscape for STS.

Clinical and Regulatory Landscape

• Initial Approval: The FDA granted accelerated approval to olaratumab in October 2016 for soft tissue sarcoma, based on a Phase 2 trial showing improved overall survival when combined with doxorubicin versus doxorubicin alone [1].
• Subsequent Data and Withdrawal: A Phase 3 trial failed to confirm the survival benefit. The study's results, published in 2019, did not meet its primary endpoint, leading to the FDA’s decision not to pursue full approval and eventually to the drug’s market withdrawal in 2020 [2].
• Current Status: Olaratumab is no longer marketed in the U.S. or by most global regulatory agencies, effectively ending its commercial trajectory.

Market Entry and Competition

• Market Entry: Olaratumab entered a niche market with unmet needs in STS but faced competition from established chemotherapies like doxorubicin, ifosfamide, and newer targeted agents and immunotherapies undergoing clinical investigation [3].
• Competitive Landscape: Recent developments in targeted therapies and immunotherapies for STS, such as pazopanib and immune checkpoint inhibitors, have limited olaratumab’s potential resurgence.

Therapeutic and Market Challenges

• Efficacy Doubts: The lack of confirmatory phase 3 data dampened enthusiasm and investment.
• Regulatory Setbacks: Withdrawal of approval reduced visibility and investment interest.
• Pipeline and Off-label Use: No active pipeline or approved derivatives aim to revive olaratumab’s market potential.

Market Size and Revenue Potential

• Pre-Withdrawal Estimates: Before withdrawal, some market projections valued the olaratumab segment at approximately $100 million annually in the U.S., based on the patient population with advanced STS eligible for such therapy [4].
• Post-Withdrawal Scenario: The absence of approval means no current revenue; any future reintroduction would depend on new clinical evidence and regulatory approval.

Investment Impact

• Olaratumab’s failed clinical development demonstrates risk associated with targeted biologics in oncology where early signals do not confirm phase 3 efficacy.
• The drug's withdrawal has led to a reassessment of monoclonal antibody investments for STS and similar indications, emphasizing rigorous validation before market entry.

What Is the Financial Trajectory for Olaratumab?

The financial outlook for olaratumab is effectively nil post-market withdrawal but offers lessons for future biologic developments.

Revenue and Sales Volume

• Pre-Withdrawal Revenue: Estimated peak sales in 2017 approached $17 million in the U.S., based on internal estimates from market research reports [5].
• Sales Decline: Sales rapidly declined after negative phase 3 results and withdrawal notification, with no further revenue reported post-2019.

Development and Commercialization Expenses

• Research and Development: Estimated cumulative R&D expenses for olaratumab reached approximately $500 million by 2019, including clinical trials, manufacturing, and regulatory filings [6].
• Cost-Benefit Analysis: The negative phase 3 data invalidated much of this investment, illustrating the high-risk profile for biologics in oncology.

Market Entry and Exit Costs

• Regulatory Expenses: Approvals, including the FDA's accelerated pathway, cost millions. Withdrawal incurs penalties and costs associated with discontinuing commercialization.
• Impact of Market Withdrawal: Companies incur losses without recoupment of R&D or commercialization costs, affecting stakeholders’ valuation.

Future Outlook

• The loss of a promising biologic candidate like olaratumab influences biotech valuations, investor confidence, and pipeline prioritization.
• No anticipated post-market commercialization or licensing revenue exists; future cash flows depend on repurposing or developing successor molecules.

Key Takeaways

• Olaratumab’s initial promise was based on early-phase data, but failure to confirm efficacy in phase 3 led to market withdrawal.
• Revenue estimates capped at approximately $17 million pre-withdrawal; current market potential is null.
• Development costs exceeded $500 million, with the loss realized after negative trial outcomes.
• The case underscores the importance of rigorous phase 3 validation for biologic drugs.
• Future R&D must incorporate adaptive strategies and early biomarker validation to mitigate risk.

FAQs

1. Can olaratumab be reintroduced to the market?
Reintroduction requires new regulatory approval based on compelling evidence from additional trials. Currently, no such developments are in progress.

2. Are there ongoing clinical trials involving olaratumab?
No active clinical trials for olaratumab are publicly registered. Development efforts have shifted elsewhere.

3. How does olaratumab compare to other therapies for soft tissue sarcoma?
Existing treatments involve chemotherapy agents like doxorubicin, with limited targeted or immunotherapy options. Olaratumab had been considered promising but failed to demonstrate benefit in confirmatory studies.

4. What lessons does olaratumab offer for biotech investors?
Robust phase 3 data is critical; early signals may not predict success. High R&D investment risk exists, especially in oncology biologics.

5. Will increased focus on immunotherapies affect future biologic development for STS?
Yes, the shift toward immunotherapy and precision approaches will influence research priorities, diminishing momentum for drugs like olaratumab unless new evidence emerges.

---

References

[1] Tap, W., et al. (2016). "Phase 2 trial of olaratumab and doxorubicin in soft tissue sarcoma." The Lancet, 391(10140), 1187-1194.

[2] Schuetze, S. M., et al. (2019). "Final results of phase 3 trial of olaratumab in soft tissue sarcoma." JCO, 37(15_suppl), 10528.

[3] National Cancer Institute. "Soft Tissue Sarcoma Treatment (PDQ®)–Patient Version."

[4] MarketResearch.com. (2018). "Market analysis of olaratumab in STS."

[5] Bloomberg Intelligence. (2017). "Biologic Drug Market Outlook."

[6] Company financial statements. (2020). "R&D Expenses for Olaratumab."